Innate Pharma SA

IPHA

Company Profile

  • Business description

    Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

  • Contact

    117, Avenue de Luminy
    Marseille13009
    FRA

    T: +33 430303030

    E: [email protected]

    https://www.innate-pharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    181

Stocks News & Analysis

stocks

Nvidia: Collaboration with Intel might bring some goodwill with the US

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
stocks

What now for Santos after takeover offer collapses?

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.
stocks

Morningstar initiates coverage on small cap ASX REIT

Coverage of ASX listed REIT as investor interest in property continues to grow.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,061.2061.30-0.67%
CAC 407,853.591.02-0.01%
DAX 4023,639.4135.12-0.15%
Dow JONES (US)46,315.27172.850.37%
FTSE 1009,216.6711.44-0.12%
HKSE26,545.10106.590.40%
NASDAQ22,631.48160.750.72%
Nikkei 22545,045.81143.540.32%
NZX 50 Index13,231.663.23-0.02%
S&P 5006,664.3632.400.49%
S&P/ASX 2008,773.5075.00-0.85%
SSE Composite Index3,820.0911.57-0.30%

Market Movers